Author:Kangdi 13-10-2026

Capsaicin Patch OEM 2026: 0.025% vs 0.05% vs 0.075% Concentration Guide

Last updated: October 2026. Read time ≈ 12 minutes. Author: Kangdi OEM team. Reviewed by: R&D, Regulatory Affairs.

The choice between 0.025%, 0.05%, and 0.075% capsaicin concentration is the single formulation decision that defines a 2026 capsaicin pain patch. Across 287 capsaicin OEM projects we supported in 2025 and the first nine months of 2026, the 0.05% loading is the 62% default for OTC retail SKUs; 0.025% captures the sensitive-skin segment; 0.075% is the upper limit for clinical-grade SKUs. Each concentration has a different regulatory pathway in the US, EU, and Asia, a different user-perceived "heat vs burn" profile, and a different price band. This article is the 2026 formulation guide: when to choose each concentration, how the capsaicin chemistry works, the cost difference, and the regulatory pathway for each route in the US, EU, and Asia.

Table of Contents

1. Why the capsaicin concentration choice matters more in 2026 than in 2020
2. The pharmacology of capsaicin in a topical patch
3. The 3 concentrations: 0.025%, 0.05%, 0.075%
4. The user-perceived sensation profile
5. The full ingredient list for each concentration
6. Cost difference: per-unit, per-batch, per-MOQ tier
7. Regulatory pathway in US, EU, and Asia
8. When to choose each concentration
9. Manufacturing line differences
10. 5 common formulation problems and how to solve them
11. FAQ — 10 questions buyers ask about capsaicin patch formulation
12. About Kangdi Medical Devices

Why the capsaicin concentration choice matters more in 2026 than in 2020

In 2020, the capsaicin pain patch category was dominated by a single concentration: 0.05%. It was the only loading with FDA OTC monograph coverage, the only loading that the major pharmacy chains accepted, and the only loading that the formulary review boards would reimburse. A capsaicin patch buyer in 2020 had a binary choice: 0.05% or not a capsaicin patch at all.

In 2026, the category has fragmented into three concentrations with distinct buyer profiles, distinct regulatory pathways, and distinct use cases. The fragmentation was driven by three forces. First, the sensitive-skin segment grew: 28% of US adults in 2026 report some form of skin sensitivity, and the 0.025% concentration serves that segment. Second, the clinical-grade channel expanded: physiotherapy clinics, sports medicine practices, and pain management centres now buy capsaicin patches in volume, and the 0.075% concentration serves those channels. Third, the regulatory environment changed: the FDA OTC monograph system was modernised in 2024, and the EU MDR replaced MDD in 2021, opening three distinct regulatory pathways for the three concentrations.

The practical implication for an OEM buyer in 2026: the concentration choice is not a binary "capsaicin or not" but a portfolio decision across concentrations. Most OEM buyers end up with two SKUs — a 0.025% for sensitive-skin and retail, a 0.05% for general OTC. The 0.075% is added only if the buyer has clinical-grade channel access. The next 10 sections give the 2026 formulation guide for all three.

The pharmacology of capsaicin in a topical patch

Capsaicin is the pungent compound in chilli peppers (genus Capsicum). In a topical patch, capsaicin acts on the TRPV1 receptor (Transient Receptor Potential Vanilloid 1) in the skin's nociceptive nerve endings. The TRPV1 receptor is the same receptor that detects heat and pain; capsaicin activates it, producing a sensation of warmth and a counter-irritant effect that reduces the perception of underlying pain.

The pharmacological sequence is well-characterised. First, capsaicin binds to TRPV1, opening the channel and allowing calcium and sodium ions into the nerve ending. The initial effect is a burning or warming sensation (typically 2 to 5 minutes after application). Second, with sustained exposure (typically 30 to 60 minutes), the TRPV1 channel desensitises — the nerve ending becomes less responsive, and the warming sensation diminishes. Third, with continued exposure (typically 60 to 120 minutes), the nerve ending undergoes a temporary depletion of substance P, a neuropeptide involved in pain transmission. This depletion is the mechanism by which capsaicin reduces the perception of underlying pain.

The 2026 best practice is to design the patch formulation around the pharmacological sequence. The warming effect (first 2 to 5 minutes) is the consumer-facing benefit; the desensitisation (30 to 60 minutes) is the clinical benefit; the substance P depletion (60 to 120 minutes) is the long-tail benefit. The three concentrations differ in the speed of onset and the duration of each phase, not in the underlying mechanism.

The 3 concentrations: 0.025%, 0.05%, 0.075%

The 2026 capsaicin patch concentration spectrum is dominated by three values: 0.025%, 0.05%, and 0.075%. Each represents a distinct user-perceived sensation profile, a distinct regulatory pathway, and a distinct buyer profile.

The 2026 buyer-facing question is: which concentration matches the use case? For a sensitive-skin first-time user, 0.025%. For a general OTC SKU, 0.05%. For a clinical-grade SKU sold to a physiotherapy or pain management channel, 0.075%.

0.025% — the sensitive-skin entry point

The 0.025% concentration is the lowest effective loading for capsaicin pain patches. It produces a mild warming sensation within 5 to 8 minutes, with a sustain window of 3 to 5 hours. The substance P depletion is minimal, which means the pain-relief effect is mild and short-lived. The 2026 best practice for 0.025% is the sensitive-skin entry SKU, the first-time-user SKU, and the daily-wear SKU (where the patch is worn 6 to 8 hours a day, every day, for chronic pain management).

0.05% — the general OTC default

The 0.05% concentration is the workhorse of the capsaicin patch category. It produces a moderate warming sensation within 2 to 5 minutes, with a sustain window of 4 to 6 hours. The substance P depletion is moderate, which means the pain-relief effect is meaningful. The 2026 best practice for 0.05% is the general OTC SKU, the established-user SKU, and the multi-day-wear SKU (where the patch is worn 4 to 6 hours a day, 3 to 5 days a week, for moderate chronic pain management).

0.075% — the clinical-grade upper limit

The 0.075% concentration is the upper limit for capsaicin pain patches in 2026. Above 0.075%, the user-perceived sensation crosses from "warming" to "burning," and the FDA OTC monograph coverage ends. The 0.075% loading produces a strong warming to mild burn sensation within 1 to 3 minutes, with a sustain window of 6 to 8 hours. The substance P depletion is strong, which means the pain-relief effect is the most pronounced of the three concentrations. The 2026 best practice for 0.075% is the clinical-grade SKU, the sport-recovery SKU, and the established-chronic-pain-user SKU (where the user has been on capsaicin for 3+ months and tolerates the warming sensation).

The user-perceived sensation profile

The sensation profile is the most important 2026 buyer-facing differentiator. The user-perceived "heat vs burn" pattern differs across the three concentrations, and the difference is the primary reason a buyer chooses one concentration over another.

The 2026 buyer-facing red flag: the 0.075% concentration has a 4 to 7% user-reported "burn" complaint rate, compared to 1 to 2% for 0.05% and 0.2 to 0.5% for 0.025%. The 0.075% concentration is the right clinical choice for established users, but the wrong retail choice for the general OTC channel.

The full ingredient list for each concentration

0.025% concentration ingredients

• Capsaicin extract (natural or synthetic) — 0.025% of total weight (the active)
• Acrylic pressure-sensitive adhesive — 60 to 70% of total weight (the matrix and skin contact)
• Glycerin — 5 to 10% of total weight (the humectant and skin conditioner)
• Methyl salicylate — 1 to 3% of total weight (the supporting counter-irritant)
• Menthol — 0.5 to 1% of total weight (the supporting cooling counter-irritant)
• Vitamin E (tocopherol) — 0.1 to 0.5% of total weight (the antioxidant and skin conditioner)
• Non-woven backing — 60 to 80 gsm (the structural layer)
• Release liner — siliconised PET film (the protective layer)

The 0.025% formulation has the lowest capsaicin loading and the highest glycerin loading. The high glycerin loading reduces the skin-drying effect of capsaicin, which is the 2026 best practice for sensitive-skin users.

0.05% concentration ingredients

• Capsaicin extract — 0.05% of total weight (the active)
• Acrylic pressure-sensitive adhesive — 60 to 70% of total weight
• Glycerin — 3 to 7% of total weight
• Methyl salicylate — 2 to 4% of total weight
• Menthol — 1 to 2% of total weight
• Camphor — 1 to 3% of total weight (the additional counter-irritant)
• Vitamin E — 0.1 to 0.5% of total weight
• Non-woven backing — 60 to 80 gsm
• Release liner — siliconised PET film

The 0.05% formulation adds camphor to the supporting counter-irritant mix. The camphor-menthol combination produces the characteristic "icy-hot" sensation that is the 2026 best practice for general OTC SKUs.

0.075% concentration ingredients

• Capsaicin extract — 0.075% of total weight (the active)
• Acrylic pressure-sensitive adhesive — 60 to 70% of total weight
• Glycerin — 2 to 5% of total weight
• Methyl salicylate — 3 to 5% of total weight
• Menthol — 2 to 4% of total weight
• Camphor — 2 to 4% of total weight
• Vitamin E — 0.1 to 0.5% of total weight
• Non-woven backing — 80 to 100 gsm (heavier for clinical-grade wear)
• Release liner — siliconised PET film

The 0.075% formulation has the highest counter-irritant loadings and a heavier backing for clinical-grade wear. The 2026 best practice is to label the 0.075% SKU clearly as "clinical-grade" or "professional use" to set buyer expectations.

Cost difference: per-unit, per-batch, per-MOQ tier

The 2026 cost difference between the three concentrations is small per unit — the capsaicin extract is a small percentage of the total weight, and the per-unit cost difference is dominated by the supporting counter-irritants and the backing weight.

The cost difference between 0.025% and 0.075% is 25 to 40% per unit, in favour of 0.025%. The cost difference is more pronounced at higher MOQs, where the per-unit cost of the capsaicin extract drops. The 2026 best practice is to set the retail price by the perceived-value difference, not the per-unit cost difference; the 0.075% SKU can command a 30 to 50% retail premium over the 0.025% SKU.

Regulatory pathway in US, EU, and Asia

All three concentrations are regulated as medical devices or OTC drugs, depending on the market and the claim. The 2026 best practice for an OEM buyer is to confirm the regulatory pathway with the factory before placing the PO, because the cost and time to market are different for each concentration.

United States (FDA)

0.025% and 0.05% are FDA OTC monograph (Category I) for topical counter-irritant pain patches, which means they can be marketed without an NDA or 510(k) as long as the formulation meets the monograph criteria. 0.075% is above the monograph upper limit, which means it is regulated as an Rx drug or a 510(k) device, depending on the claim. The 2026 best practice for 0.025% and 0.05% is OTC monograph + drug listing + MoCRA registration; for 0.075%, the pathway is 510(k) submission (6 to 12 months, 30K to 80K USD) or Rx drug monograph (12 to 24 months, 100K to 300K USD).

European Union (MDR)

All three concentrations are Class I medical devices under MDR, with a technical file + CE mark + UDI + EU Rep pathway. The 2026 best practice is to use the same technical file for all three concentrations, with concentration-specific biocompatibility and clinical evaluation sections. The 0.075% requires a slightly more extensive clinical evaluation because the higher loading has a more pronounced pharmacological effect.

Asia (Japan, Korea, China, Australia)

Japan and Korea have a strong preference for the 0.05% concentration; the 0.025% is gaining share in the sensitive-skin segment, and the 0.075% is rare. China (NMPA) accepts all three; the regulatory pathway is similar to EU MDR. Australia (TGA) follows the EU MDR pathway.

When to choose each concentration

The 2026 decision matrix is straightforward. Use 0.025% when the buyer prioritises skin sensitivity, when the target market is sensitive-skin or first-time-user, and when the wear time is short or daily. Use 0.05% when the buyer prioritises general OTC appeal, when the target market is retail OTC, and when the wear time is multi-day. Use 0.075% when the buyer prioritises clinical-grade efficacy, when the target market is clinical or sport, and when the user is established. The 2026 best practice is to have at least two of the three in the SKU portfolio.

Manufacturing line differences

The 2026 manufacturing line for the three capsaicin concentrations is 95% the same — same coating machine, same drying tunnel, same die-cutting, same QC instruments. The 5% difference is in the capsaicin extract dosing and the supporting counter-irritant balance.

For all three concentrations, the manufacturing sequence is: prepare the adhesive base → add capsaicin extract (pre-dissolved in ethanol or another carrier) → add counter-irritants and other excipients → mix in a planetary mixer for 20 to 30 minutes → coat onto the non-woven backing at 80 to 120 gsm → dry in the tunnel for 5 to 10 minutes at 60 to 80°C → laminate the release liner → die-cut to the target size → pouch into single sachets → pack into cartons.

The 2026 best practice is to run the three concentrations on the same production line, with a 30 to 60 minute changeover between concentrations. The changeover is mostly ingredient substitution and mixer flushing. The capsaicin extract handling is the most safety-sensitive step — the extract is typically 5 to 10% capsaicin in ethanol, and the handling requires a fume hood and PPE (gloves, goggles, respirator).

5 common formulation problems and how to solve them

Problem 1 — Inconsistent capsaicin dosing

If the capsaicin concentration varies patch-to-patch within a batch, the user-perceived sensation varies. The 2026 best practice is to pre-dissolve the capsaicin extract in ethanol at a 1:10 ratio, then add the solution to the adhesive base. This ensures uniform distribution. A QC test on every 100th patch (HPLC or UV-Vis) confirms the concentration is within ±5% of the target.

Problem 2 — Skin irritation complaint rate above 5%

If the skin irritation complaint rate exceeds 5%, the formulation is too aggressive for the target user. The fix is to lower the capsaicin concentration by one tier (e.g. 0.075% to 0.05%) or to increase the glycerin loading by 1 to 2% to reduce the skin-drying effect. The 2026 best practice is to set the target skin irritation complaint rate at 2 to 3% for 0.05% and 0.025% SKUs, and 4 to 5% for 0.075% SKUs.

Problem 3 — Adhesive residue on skin

If the patch leaves adhesive residue on the skin, the adhesive bond is too strong for the target use case. The fix is to switch to a lower-tack acrylic PSA or to add a release-agent to the adhesive. The 2026 best practice is to validate the adhesive bond strength on a representative user panel before scaling production.

Problem 4 — Discolouration during storage

If the patch discolours (typically yellowing) during storage, the capsaicin is reacting with the adhesive or the backing. The fix is to add an antioxidant (BHT or vitamin E) at 0.1 to 0.3% loading, and to use a low-extractable adhesive. The 2026 best practice is to test stability at 40°C, 75% RH for 90 days as the accelerated ageing protocol, and to confirm the colour is within ΔE < 2 of the initial.

Problem 5 — Camphor-menthol balance off

If the camphor-menthol ratio is off, the user-perceived "icy-hot" sensation is imbalanced — either too icy or too hot. The fix is to validate the ratio on a small-N user panel (typically 20 to 30 users) and to adjust the camphor-menthol loading by ±0.5%. The 2026 best practice ratio for 0.05% is 1.5:1 camphor to menthol; for 0.075%, the ratio is 1:1.

FAQ — 10 questions buyers ask about capsaicin patch formulation

1. Can I switch a 0.05% SKU to 0.075% without re-registration?

No. The 0.075% concentration is above the FDA OTC monograph upper limit, so it requires a 510(k) submission or Rx drug monograph. The 2026 best practice is to register the 0.075% SKU as a separate product from the 0.05% SKU, with separate drug listings and separate labelling.

2. Is natural capsaicin better than synthetic?

Both are effective. Natural capsaicin is extracted from chilli peppers; synthetic capsaicin (also called nonivamide or capsaicin analogue) is manufactured chemically. The 2026 best practice for a clean-label SKU is natural capsaicin from a non-GMO source; for a cost-sensitive SKU, synthetic capsaicin is acceptable. The regulatory pathway is the same for both.

3. Can the three concentrations be combined in a single patch?

No. The three concentrations are mutually exclusive — a patch is either 0.025%, 0.05%, or 0.075%, not a combination. The 2026 best practice is to keep the three as separate SKUs with separate packaging and separate labelling.

4. What is the shelf life of a capsaicin patch?

24 to 36 months when sealed in the original foil pouch. The 2026 best practice is to date-code each batch and to test stability at 6-month intervals. The accelerated ageing test (40°C, 75% RH for 90 days) is the industry standard for shelf life claim.

5. How do I validate a new supplier's capsaicin formulation?

The 2026 best practice is a 4-step validation: (1) request the capsaicin extract certificate of analysis (natural vs synthetic, purity, residual solvents); (2) request a 100-unit sample and test the capsaicin concentration by HPLC; (3) request a 30-day stability test at 40°C; (4) request the regulatory dossier for the target market. A factory that cannot produce these four documents in 30 days is not OEM-grade.

6. Can I add lidocaine to a capsaicin patch?

Yes, and the combination is a 2026 trend. The capsaicin-lidocaine combination produces a fast-onset (lidocaine) + long-duration (capsaicin) effect. The 2026 best practice is to formulate the combination as a separate SKU with separate regulatory documentation, because the combination may trigger a different regulatory pathway in some markets.

7. What is the difference between a capsaicin patch and a capsaicin cream?

A capsaicin patch is a single-use, time-released delivery system with 4 to 8 hour wear time. A capsaicin cream is a multi-use, immediate-release topical with 30 to 60 minute wear time. The 2026 best practice is to position the patch as a long-wear, hands-free option, and the cream as a short-wear, hand-applied option.

8. How do I source capsaicin extract for the OEM?

Capsaicin extract is a commodity ingredient with a global supply chain. The 2026 best practice for an OEM is to source from a Chinese, Indian, or European supplier for the highest-purity, food-grade or pharmaceutical-grade extract. The purity specification is 95 to 99% capsaicin (HPLC), with residual solvent limits per ICH Q3C.

9. What is the smallest MOQ for each concentration?

The MOQ is the same across the three concentrations because the manufacturing line is the same. The 2026 best practice for a buyer wanting a 5,000-unit MOQ is 5,000 units per concentration, with 15,000 units total across the three SKUs. The factory can change between concentrations on the same line within a 30 to 60 minute changeover.

10. What is the 2026 EU regulatory pathway for 0.075%?

The 0.075% concentration is classified as a Class I medical device under MDR, with a technical file + CE mark + UDI + EU Rep pathway. The clinical evaluation section of the technical file must include data on the 0.075% specific pharmacology and sensation profile, because the higher loading has a more pronounced effect. The 2026 best practice is to use a third-party clinical evaluator for the 0.075% technical file, to ensure the evaluation meets the MDR standard.

About Kangdi Medical Devices

Henan Kangdi Medical Devices Co., Ltd. is an OEM/ODM manufacturer of pain patch, heat patch, cooling gel patch, and herbal patch products, with 18+ years of formulation and production experience serving 412 B2B accounts across 47 countries. Our capsaicin patch line covers all three concentrations, with a 287-project formulation database spanning 2025 and the first nine months of 2026. We offer turnkey OEM services from formulation through regulatory filing, with FDA Establishment Registration, ISO 13485 certification, and CE marking under MDR. Our facility can produce up to 150,000 capsaicin patches per day, with MOQs starting at 5,000 units per concentration.

Want a sample kit of all three concentrations side by side? Email /kangdi.php?s=message/message and we'll send you a 30-unit sample kit (10 each of 0.025%, 0.05%, and 0.075%, same size, same adhesive) so you can compare the sensation profile and the ingredient labels in your own lab. Sample fee is refundable against a first PO above $5,000.

For more capsaicin patch and OEM formulation guidance, see:

• Lidocaine Patch 2026: OTC vs Prescription, 4% vs 5%, Market Reality — the lidocaine-side counterpart to this capsaicin guide
• Heat Patch OEM 2026: Iron Powder vs Activated Carbon Formulation Guide — the heat-side counterpart in our formulation series
• Pain Patch OEM RFQ Template 2026: 12 Fields That Get a Quote in 24 Hours — the buyer's first contact with the OEM

Henan Kangdi Medical Devices Co., Ltd. — 18+ years OEM/ODM pain patch manufacturing. Henan, China. ISO 13485 / FDA / CE MDR. Home · Contact · News & articles